[go: up one dir, main page]

EP2407132B1 - Device for preparing an eye for introducing a photostabilizer - Google Patents

Device for preparing an eye for introducing a photostabilizer Download PDF

Info

Publication number
EP2407132B1
EP2407132B1 EP10006607.5A EP10006607A EP2407132B1 EP 2407132 B1 EP2407132 B1 EP 2407132B1 EP 10006607 A EP10006607 A EP 10006607A EP 2407132 B1 EP2407132 B1 EP 2407132B1
Authority
EP
European Patent Office
Prior art keywords
eye
channels
tissue
computer
programmed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP10006607.5A
Other languages
German (de)
French (fr)
Other versions
EP2407132A1 (en
Inventor
Theo Prof.Dr. Dr. Seiler
Theo G. Jun. Seiler
Johannes Krause
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wavelight GmbH
Original Assignee
Wavelight GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wavelight GmbH filed Critical Wavelight GmbH
Priority to ES10006607.5T priority Critical patent/ES2469868T3/en
Priority to EP10006607.5A priority patent/EP2407132B1/en
Publication of EP2407132A1 publication Critical patent/EP2407132A1/en
Application granted granted Critical
Publication of EP2407132B1 publication Critical patent/EP2407132B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/008Methods or devices for eye surgery using laser
    • A61F9/00825Methods or devices for eye surgery using laser for photodisruption
    • A61F9/00827Refractive correction, e.g. lenticle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/008Methods or devices for eye surgery using laser
    • A61F2009/00861Methods or devices for eye surgery using laser adapted for treatment at a particular location
    • A61F2009/00872Cornea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007Methods or devices for eye surgery
    • A61F9/008Methods or devices for eye surgery using laser
    • A61F2009/00897Scanning mechanisms or algorithms

Definitions

  • the invention relates to a device for preparing an eye for the introduction of photosensitizer in ocular tissue with a source of laser radiation, means for guiding and focusing the laser radiation with respect to the ocular tissue and with a computer for controlling said means.
  • the invention also relates to a corresponding method for preparing an eye for the introduction of photosensitizer using laser radiation.
  • the human eyeball is bounded by the outer eye skin. Due to the intraocular pressure, the collagen-containing outer eye skin is stretched and gives the healthy eyeball an approximately spherical shape.
  • the outer eye skin consists of the white dermis (sclera).
  • the front area is the visible light permeable cornea (cornea).
  • Deformations of the outer eye skin can be the cause of ametropia.
  • a form of myopia the axis myopia
  • An ellipsoidal surface of the cornea may result in a form of astigmatism, also known as astigmatism.
  • Another disease of the cornea is called keratoconus.
  • keratoconus due to morbid softening of the cornea, there is a progressive thinning and conical deformation of the cornea of the eye. As the bulge increases, the cornea below the center becomes thinner. It can break through and scar. This permanently reduces the visual acuity.
  • the causes of keratoconus are still largely unknown today. He occurs familial heaped up, which among other things suggests a genetic disposition. Another risk factor for the development of keratoconus is atopy, such as allergic diseases.
  • the conventional therapy of advanced keratoconus is to remove the diseased cornea and replace it with an allograft.
  • an organ transplantation with the associated risks and complications.
  • Adequate vision is often achieved approximately two years after surgery.
  • corneal transplantation in keratoconus mostly affects young people, which is why the transplant must work flawlessly for decades.
  • An improved therapy of keratoconus stabilizes the cornea by cross-linking.
  • the treatment allows photochemical, non-tissue-removing stabilization or alteration of the biomechanical and biochemical properties of the cornea.
  • the treatment principle is also applicable to other affected regions of the eye.
  • a photosensitizer solution is introduced into the eye tissue to be altered and exposed to primary radiation.
  • the primary radiation used is electromagnetic radiation in the wavelength range from about 300 nm to 800 nm (UV-A radiation or visible light).
  • Corresponding devices for the treatment of the outer eye skin are known from the documents WO 2007/128581 A2 and WO 2008/000478 A1 known.
  • the EP 1 561 440 B1 describes a device in which a homogeneous distribution of the radiation in the ocular tissue is produced with a relatively complex structure. A shaped body is placed there on the cornea to bring it into a desired shape while using electromagnetic radiation and the photosensitizer the ocular tissue is changed in terms of its strength. Such a shaped body can also be used in connection with the present invention.
  • a device serves to solidify the sclera located in the posterior part of the eye.
  • the primary radiation can act on the sclera through the interior of the eye or by lying on the outside pillows.
  • a photoinitiator or photosensitizer causes cross-linking in the sclera. This counteracts scleral growth and prevents progression of axonal myopia.
  • the EP 1 854 438 A1 describes an ophthalmic device for the prevention of myopia, in which the sclera is solidified by means of a photosensitizer.
  • the publication WO 2008/000478 A1 describes an irradiation system for biomechanical stabilization of the cornea.
  • crosslinking at the cornea can be effected in conjunction with a photosensitizer.
  • the radiation system offers the possibility to treat specific diseases, such as keratoconus.
  • the US 2009/187171 A1 describes producing cuts in volumes within the stroma, with the volumes completely in the stroma. This is to change the shape of the cornea due to the intraocular pressure.
  • riboflavin has proven to be advantageous as a photosensitizer.
  • the corneal epithelium In order to introduce riboflavin into the cornea, in the prior art, the corneal epithelium must be at least partially removed because it hinders the penetration of riboflavin into the cornea, so to speak represents a barrier to the diffusion of riboflavin molecules into the corneal tissue.
  • the removal is The epithelium usually associated with pain for the patient and also the subsequent healing process is not always without complications.
  • the invention has for its object to provide a device of the type mentioned, which allows a gentle introduction of the photosensitizer in the eye tissue, especially in terms of depth.
  • the cross-linking in ocular tissue should also be controllable in a simple manner.
  • the invention provides a device according to claim 1 for preparing an eye for the introduction of photosensitizer in ocular tissue.
  • the laser radiation used to create the channel or channels can be generated by means known as such.
  • femto-LASIK There laser radiation is used, for example, a femtosecond laser as a so-called “laser scalpel” to cut eye tissue by "evaporation” (cavitation bubbles) with the energy of the laser light.
  • femto-LASIK the so-called flap cut is produced with the laser scalpel, ie a lid is cut out of the epithelium from the side and folded away.
  • an excimer laser in the exposed stroma to ablate the cornea to perform an ablation.
  • Pulsed lasers with pulse lengths in the picosecond range and in the nanosecond range are also suitable for generating the channels.
  • channel in the sense of the present invention does not mean a cut surface for producing a so-called flap, as it is known in femtosecond LASIK.
  • the means used for the present invention for guiding and focusing the laser radiation with respect to the eye tissue can be taken from this technique.
  • the computer controlling the optical means for guiding and focusing the laser radiation is, according to the invention, programmed in such a way that the foci of the laser radiation successively follow one another Straight or curved line are moved so that so-called cavitation bubbles in the tissue, a channel or multiple channels arise, which extend from the surface of the eye tissue, ie in particular the cornea, in the interior of the eye tissue, so that a photosensitizer, which at the entrance of the Channel is brought into the canal and thus into the interior of the eye tissue can penetrate.
  • the channels are preferably produced in such a way that the individual adjacent cavitation bubbles each have such a distance from each other ("spacing") that the structure and stability of the tissue is impaired as little as possible.
  • the distance between the cavitation bubbles which produce the channel should also be so small that the photosensitizer introduced into the channel in the form of a solution, e.g. B. riboflavin, penetrates in the desired manner through the channel, so to speak, from Kavitationsblase to Kavitationsblase in the tissue. In the areas between adjacent cavitation bubbles, therefore, the penetration of the photosensitizer solution takes place by diffusion.
  • the term "channel” is not necessarily to be understood as a continuous, completely tissue-free cavity, although on the other hand, completely continuous channels within the meaning of the invention are conceivable.
  • the channel can also follow a curved line, since by focusing the laser radiation in the interior of the tissue with focus points along the curved line, a channel shape deviating from the straight line can be generated.
  • a channel shape deviating from the straight line can be generated.
  • channel shapes can be created by stringing the foci of the laser radiation with a sufficiently dense distance through them so-called "photodisruption" of the channel with the desired diameter and with the desired geometric course.
  • the invention also makes it possible to adjust the density of the channels in the eye tissue differently, depending on the location in the eye tissue, ie to set more channels at desired sites of the eye tissue than at other locations, which then has the consequence that where the canal density is greater is also the density of the photosensitizer in the tissue is higher and thus the biomechanical and biochemical effect at such sites is different than those in the eye tissue in which the channel density is lower.
  • the density of the photosensitizer ultimately acting in the eye tissue can also be controlled by varying the depth of the channels in the cornea in a location-dependent manner.
  • the density of the photosensitizer to be introduced into the eye tissue can be controlled by making the cross section of the one or more channels more or less large.
  • the width of a channel is preferably in the range of 0.1 mm 2 to 1.2 mm, with each subinterval therein also disclosed herein.
  • a channel system can be created in the cornea, which allows access from the outside to the interior of the cornea.
  • the photosensitizer solution can then be injected so that it spreads in the corneal stroma.
  • the channel system depending on the ophthalmological indication, have one or more channels, for example, with a desired homogeneous distribution of the photosensitizer, the density of the channels (ie the number of channels per unit area or per unit volume) is substantially homogeneous in the treated area the cornea.
  • four channels may be placed in the four corneal segments, corresponding to the four segments of corneal projection onto a plane.
  • the channel system can also be generated stochastically.
  • cross-sections of the individual channels can be designed by appropriate control of the focuses of the laser radiation optionally, for example, circular, rectangular, square, or even oval or slit-shaped.
  • the channels extend substantially transversely to the axis (A) of the eye.
  • transverse here essentially means “radial”.
  • Diadial means a direction outward from the apex of the cornea.
  • An embodiment of the invention provides that the channel (s) traverses substantially the entire radial surface of the cornea with a substantially uniform channel density. This means, in other words, that at least in a given area at a given depth the cornea photosensitizer is brought into the comatom by diffusion homogeneously (uniformly with the same density).
  • the one or more channels are connected to more than one opening, said one
  • Opening in the surface of the eye tissue is sufficient so that photosensitizer without obstruction in the one or more channels can be introduced, for. B. with a fine syringe or the like.
  • the said openings, through which the channels are accessible from the outside, are preferably arranged at or near the edge of the cornea, ie at or near the limbus.
  • channels or cavities in the sense of the present invention is thus different from the generation of a so-called flap for the LASIK, d. H. the channels or cavities according to the invention do not cause the generation of a flap ("Deckelchens"), which can be folded to the side.
  • Another preferred embodiment of the invention provides that at least a part of the channels runs in a spiral shape.
  • a gas in particular air, can be injected into one or more channels or cavities.
  • Fig. 1 schematically shows an eye 10 to be changed by introducing photosensitizer with regard to its biomechanical and / or biochemical properties.
  • this process is known as "corneal crosslinking.”
  • the cross-linking so-called cross-linking, enhances the mechanical stability of the cornea.
  • the use of moldings can also change the shape of the cornea during channeling or cross-linking.
  • the use of photosensitizers is also suitable for treating infectious inflammations of the cornea, with the resulting radicals killing invading germs.
  • An eye axis is designated by "A", this eye axis substantially coinciding with the optical axis of the means described below in more detail for guiding and focusing laser radiation.
  • the center (center) of the corneal surface (14a) is denoted by "M", so that a radial direction R can be defined therefrom.
  • the eye tissue 12 to be cross-linked is substantially the cornea (cornea) 16 which is covered outwardly by the epithelium 14.
  • channels 18 are inserted into the cornea 16, the channels 18 being fluidly connected to ports 0 (ports), and the ports O allowing external access to the channels for entering photosensitizer solution ,
  • the channels 18 extend into the interior of the cornea 16 and terminate before the inner surface 16 a.
  • a photosensitizer for example riboflavin, is introduced, which penetrates into the channels and spreads therefrom by diffusion in the corneal tissue.
  • the device has a source 20 for laser radiation, for example a femtosecond laser as explained above, as for example for cutting a flap in the femto-LASIK is used.
  • a source 20 for laser radiation for example a femtosecond laser as explained above, as for example for cutting a flap in the femto-LASIK is used.
  • the means 24 for guiding and focusing the laser radiation 26 in the interior of the cornea 16 appropriate means known per se from femto-LASIK can also be used.
  • a computer 22 which controls the laser beam source 20 and the optical means 24 for guiding and focusing the laser radiation 26, is programmed with a program P which controls the laser radiation 26 in a special way for generating the channels 18.
  • a program P which controls the laser radiation 26 in a special way for generating the channels 18.
  • the representation according to Fig. 1 shows a section A containing the axis A through the eye.
  • a channel 18 is shown which is substantially parallel to the surface 14a of the cornea.
  • the channel is accessible via an opening O, which is located near the limbus 30, from the outside.
  • a fine syringe may be introduced into the opening O to inject a photosensitizer solution or a gas, such as air, into the channel 18.
  • Fig. 2 shows a plan view of a cornea 16 and a running inside the cornea 16 channel 18 which is in the illustrated embodiment is spiral with additional openings O, which are distributed in the circumferential direction C at intervals.
  • the approximately spirally extending channels 18 are arranged in the illustrated embodiment in a surface which extends substantially parallel to the surface 14a of the eye.
  • the channels 18 may also be arranged in a plane which is perpendicular to the axis A.
  • a variation provides that the channels extend in a plane that extends parallel to the back surface 16a of the cornea 16. *** " The choice of location and course of the channels 18 may depend on the given medical indication and be chosen accordingly.
  • the channels are positioned such that, at least in the area they define, the photosensitizer diffuses there substantially homogeneously in the corneal tissue.
  • channels may also be axial, i. parallel to the axis A, at least partially.
  • Channels may also extend radially.
  • the distribution of photosensitizer in the cornea can be optionally controlled, depending on the medical indication.
  • the channels are formed by focused laser radiation, in particular by means of a femtosecond laser, by cavitation bubbles generated by the laser focusses.
  • cavitation bubbles generated by the laser focusses.
  • adjacent cavitation bubbles do not completely overlap so that tissue residues remain between individual cavitation bubbles, which on the one hand stabilize the overall tissue in the structure and on the other hand are sufficiently permeable to the diffusion of photosensitizer in the channels.
  • Fig. 3 shows in axial plan view a cornea with a channel system 18 ', 18 ", which is shaped in the shape of a sector of a circle (as shown) for the treatment of astigmatism in the contour Fig. 3 be formed two circular sector-shaped channel systems 18 'and 18 ", each with a different sector angle ⁇ 1 and ⁇ 2 .
  • Fig. 4 shows channels 18a, 18b, 18c which extend at different depths relative to the surface 14a of the cornea.
  • the various three depths for the channels shown schematically may be used for all of the structures and arrangements of channels detailed herein FIGS. 1, 2 . 3 and 5 as well as other embodiments.
  • Fig. 5 shows an annular channel 18 "'in a schematic plan view with two openings O, which connect the channel 18"' with the surface of the cornea.
  • a modification of the embodiment according to Fig. 5 can also be provided a plurality of annular channels, which are connected fluid-conducting either with each other and / or each individually with the surface of the cornea.

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Optics & Photonics (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Laser Surgery Devices (AREA)

Description

Die Erfindung betrifft eine Vorrichtung zum Präparieren eines Auges für das Einbringen von Photosensibilisator in Augengewebe mit einer Quelle für Laserstrahlung, Mitteln zum Führen und Fokussieren der Laserstrahlung in Bezug auf das Augengewebe und mit einem Rechner zum Steuern der genannten Mittel. Auch betrifft die Erfindung ein entsprechendes Verfahren zum Präparieren eines Auges für das Einbringen von Photosensibilisator unter Verwendung von Laserstrahlung.The invention relates to a device for preparing an eye for the introduction of photosensitizer in ocular tissue with a source of laser radiation, means for guiding and focusing the laser radiation with respect to the ocular tissue and with a computer for controlling said means. The invention also relates to a corresponding method for preparing an eye for the introduction of photosensitizer using laser radiation.

In der Ophthalmologie ist seit mehr als 10 Jahren bekannt, mittels eines sogenannten Photosensibilisators und elektromagnetischer Strahlung die biomechanischen und biochemischen Eigenschaften von Augengewebe, insbesondere der Kornea, zu therapeutischen Zwecken zu ändern.In ophthalmology it has been known for more than 10 years to change the biomechanical and biochemical properties of ocular tissue, in particular of the cornea, for therapeutic purposes by means of a so-called photosensitizer and electromagnetic radiation.

Der menschliche Augapfel wird durch die äußere Augenhaut begrenzt. Durch den Augeninnendruck wird die kollagenhaltige äußere Augenhaut gespannt und verleiht dem gesunden Augapfel eine annähernd sphärische Form. Im hinteren Augapfelbereich besteht die äußere Augenhaut aus der weißen Lederhaut (Sklera). Im vorderen Bereich befindet sich die für sichtbares Licht durchlässige Hornhaut (Kornea).The human eyeball is bounded by the outer eye skin. Due to the intraocular pressure, the collagen-containing outer eye skin is stretched and gives the healthy eyeball an approximately spherical shape. In the posterior part of the eyeball, the outer eye skin consists of the white dermis (sclera). In the front area is the visible light permeable cornea (cornea).

Verformungen der äußeren Augenhaut können Ursache einer Fehlsichtigkeit sein. Beispielsweise kann eine Form der Kurzsichtigkeit, die Achsenmyopie, Folge eines skleraren Längenwachstums des Augapfels sein. Eine als Ellipsoid geformte Oberfläche der Kornea kann zu einer Form des Astigmatismus führen, welcher auch als Hornhautverkrümmung bezeichnet wird. Eine weitere Erkrankung der Hornhaut wird als Keratokonus bezeichnet. Beim Keratokonus kommt es infolge einer krankhaften Erweichung der Hornhaut zu einer fortschreitenden Ausdünnung und kegelförmigen Verformung der Hornhaut des Auges. Mit der zunehmenden Auswölbung wird die Hornhaut unterhalb des Zentrums dünner. Sie kann durchbrechen und vernarben. Das setzt die Sehschärfe dauerhaft herab. Die Ursachen des Keratokonus sind heutzutage noch weitgehend unbekannt. Er tritt familiär gehäuft auf, was unter anderem auf eine genetische Disposition schließen lässt. Einen weiteren Risikofaktor für die Entstehung eines Keratokonus stellen Atopien, wie allergische Erkrankungen, dar.Deformations of the outer eye skin can be the cause of ametropia. For example, a form of myopia, the axis myopia, may be the result of scleral longitudinal growth of the eyeball. An ellipsoidal surface of the cornea may result in a form of astigmatism, also known as astigmatism. Another disease of the cornea is called keratoconus. In keratoconus, due to morbid softening of the cornea, there is a progressive thinning and conical deformation of the cornea of the eye. As the bulge increases, the cornea below the center becomes thinner. It can break through and scar. This permanently reduces the visual acuity. The causes of keratoconus are still largely unknown today. He occurs familial heaped up, which among other things suggests a genetic disposition. Another risk factor for the development of keratoconus is atopy, such as allergic diseases.

Die konventionelle Therapie eines fortgeschrittenen Keratokonus sieht vor, die erkrankte Kornea zu entfernen und durch ein allogenes Transplantat zu ersetzen. Eine solche Operation ist jedoch eine Organverpflanzung mit den damit verbundenen Risiken und Komplikationen. Ein angemessenes Sehvermögen wird häufig erst ca. zwei Jahre nach der Operation erreicht. Zudem betrifft die Hornhautverpflanzung beim Keratokonus meist junge Menschen, weshalb das Transplantat über Jahrzehnte hinweg einwandfrei funktionieren muss.The conventional therapy of advanced keratoconus is to remove the diseased cornea and replace it with an allograft. However, such an operation is an organ transplantation with the associated risks and complications. Adequate vision is often achieved approximately two years after surgery. In addition, corneal transplantation in keratoconus mostly affects young people, which is why the transplant must work flawlessly for decades.

Eine demgegenüber verbesserte Therapie des Keratokonus stabilisiert die Kornea durch Vernetzung. Die Behandlung erlaubt eine photochemische, nichtgewebeabtragende Stabilisierung oder Veränderung der biomechanischen und biochemischen Eigenschaften der Kornea. Das Behandlungsprinzip ist auch auf andere betroffene Regionen des Auges anwendbar. Eine Photosensibilisatorlösung wird in das zu verändernde Augengewebe eingebracht und einer Primärstrahlung ausgesetzt. Als Primärstrahlung wird elektromagnetische Strahlung im Wellenlängenbereich von etwa 300 nm bis 800 nm (UV-A-Strahlung oder sichtbares Licht) eingesetzt.An improved therapy of keratoconus stabilizes the cornea by cross-linking. The treatment allows photochemical, non-tissue-removing stabilization or alteration of the biomechanical and biochemical properties of the cornea. The treatment principle is also applicable to other affected regions of the eye. A photosensitizer solution is introduced into the eye tissue to be altered and exposed to primary radiation. The primary radiation used is electromagnetic radiation in the wavelength range from about 300 nm to 800 nm (UV-A radiation or visible light).

Entsprechende Vorrichtungen zur Behandlung der äußeren Augenhaut sind aus den Druckschriften WO 2007/128581 A2 und WO 2008/000478 A1 bekannt.Corresponding devices for the treatment of the outer eye skin are known from the documents WO 2007/128581 A2 and WO 2008/000478 A1 known.

Die EP 1 561 440 B1 beschreibt eine Vorrichtung, bei der mit einem relativ komplexen Aufbau eine homogene Verteilung der Strahlung im okulärem Gewebe erzeugt wird. Ein Formkörper wird dort auf die Hornhaut aufgesetzt, um diese in eine gewünschte Form zu bringen während mittels elektromagnetischer Strahlung und des Photosensibilisators das okuläre Gewebe hinsichtlich seiner Festigkeit geändert wird. Ein solcher Formkörper kann auch im Zusammenhang mit der vorliegenden Erfindung eingesetzt werden.The EP 1 561 440 B1 describes a device in which a homogeneous distribution of the radiation in the ocular tissue is produced with a relatively complex structure. A shaped body is placed there on the cornea to bring it into a desired shape while using electromagnetic radiation and the photosensitizer the ocular tissue is changed in terms of its strength. Such a shaped body can also be used in connection with the present invention.

Eine Vorrichtung gemäß WO 2007/128581 A2 dient der Verfestigung der sich im hinteren Augenabschnitt befindenden Sklera. Die Primärstrahlung kann dabei durch das Innere des Auges oder durch von außen aufliegenden Kissen auf die Sklera einwirken. Durch einen Photomediator oder Photosensibilisator wird eine Vernetzung in der Sklera bewirkt. Dadurch wird einem Sklerawachstum entgegengewirkt und ein Fortschreiten der Achsenmyopie unterbunden.A device according to WO 2007/128581 A2 serves to solidify the sclera located in the posterior part of the eye. The primary radiation can act on the sclera through the interior of the eye or by lying on the outside pillows. A photoinitiator or photosensitizer causes cross-linking in the sclera. This counteracts scleral growth and prevents progression of axonal myopia.

Die EP 1 854 438 A1 beschreibt eine ophthalmalogische Vorrichtung zur Vorbeugung einer Myopie, bei der die Sklera mittels eines Photosensibilisators verfestigt wird.The EP 1 854 438 A1 describes an ophthalmic device for the prevention of myopia, in which the sclera is solidified by means of a photosensitizer.

Die Druckschrift WO 2008/000478 A1 beschreibt ein Bestrahlungssystem zur biomechanischen Stabilisierung der Kornea. Auch hier kann in Verbindung mit einem Photosensibilisator eine Vernetzung an der Kornea bewirkt werden. Das Bestrahlungssystem bietet die Möglichkeit spezifische Erkrankungen, wie den Keratokonus zu therapieren.The publication WO 2008/000478 A1 describes an irradiation system for biomechanical stabilization of the cornea. Here too, crosslinking at the cornea can be effected in conjunction with a photosensitizer. The radiation system offers the possibility to treat specific diseases, such as keratoconus.

Die US 2009/187171 A1 beschreibt das Erzeugen von Schnitten in Volumina innerhalb des Stromas, wobei die Volumina vollständig im Stroma liegen. Damit soll aufgrund des intraokularen Druckes die Form der Kornea geändert werden.The US 2009/187171 A1 describes producing cuts in volumes within the stroma, with the volumes completely in the stroma. This is to change the shape of the cornea due to the intraocular pressure.

Die Änderung der Gestalt und/oder von mechanischen Eigenschaften von Augengewebe, insbesondere der Hornhaut und allgemein der Sklera mittels eines eingebrachten Photosensibilisators und elektromagnetischer Strahlung ist als solche im Stand der Technik, insbesondere wie oben genannt, gut bekannt. Hinsichtlich der chemischen Zusammensetzung des Photosensibilisators wird auf den Stand der Technik verwiesen, auch hinsichtlich der eingesetzten Art der elektromagnetischen Strahlung, insbesondere der geeigneten Wellenlängen in Verbindung mit bestimmten Photosensibilisatoren.The change in shape and / or mechanical properties of ocular tissue, especially the cornea and generally the sclera by means of an incorporated photosensitizer and electromagnetic radiation is well known as such in the art, especially as mentioned above. With regard to the chemical composition of the photosensitizer, reference is made to the prior art, also with regard to the type of electromagnetic radiation used, in particular the suitable wavelengths associated with certain photosensitizers.

Einem routinemäßigen Einsatz der Vemetzungstherapie am Augengewebe stehen jedoch komplexe Abhängigkeiten entgegen. Die Beziehungen zwischen den eingesetzten Dosen und deren Wirkung im Augengewebe sind sehr vielfältig. Als Dosis in diesem Sinne kommen insbesondere in Betracht die elektromagnetische Strahlung hinsichtlich ihrer Intensität sowie ihrer Verteilung in Raum und Zeit; der eingesetzte Photosensibilisator hinsichtlich seiner chemischen Struktur, Konzentration, und Einwirkung in Raum und Zeit. Die Wirkungen von unterschiedlichen Dosen dieser Parameter auf und in dem Augengewebe eines Patienten sind sehr stark abhängig von Eigenschaften (Messdaten) bezüglich des Patienten. Dabei ist insbesondere zu berücksichtigen, dass die Wirkung der mit der Strahlung und dem Photosensibilisator durchgeführten Vernetzung auch unerwünscht sein kann bis hin zu einer Schädigung des Augengewebes oder der Funktion des Auges.However, a routine use of the crosslinking therapy on the ocular tissue is precluded by complex dependencies. The relationships between the doses used and their effect in eye tissue are very diverse. As a dose in this sense, in particular, the electromagnetic radiation in terms of their intensity and their distribution in space and time; the photosensitizer used in terms of its chemical structure, concentration, and exposure in space and time. The effects of different doses of these parameters on and in the ocular tissue of a patient are very dependent on characteristics (measurement data) relating to the patient. It should be noted in particular that the effect of the crosslinking carried out with the radiation and the photosensitizer may also be undesirable up to damage to the eye tissue or the function of the eye.

Als Photosensibilisator hat sich zur Zeit weitgehend Riboflavin als vorteilhaft erwiesen. Um Riboflavin in die Kornea (Hornhaut) einzubringen, muss im Stand der Technik das Hornhautepithel zumindest teilweise entfernt werden, da es das Eindringen von Riboflavin in die Hornhaut behindert, also sozusagen eine Schranke für die Diffusion der Riboflavin-Moleküle in das Hornhautgewebe darstellt. Allerdings ist das Entfernen des Epithels in der Regel mit Schmerzen für den Patienten verbunden und auch der anschließende Heilungsprozess nicht immer ohne Komplikationen.Currently, riboflavin has proven to be advantageous as a photosensitizer. In order to introduce riboflavin into the cornea, in the prior art, the corneal epithelium must be at least partially removed because it hinders the penetration of riboflavin into the cornea, so to speak represents a barrier to the diffusion of riboflavin molecules into the corneal tissue. However, the removal is The epithelium usually associated with pain for the patient and also the subsequent healing process is not always without complications.

Der Erfindung liegt die Aufgabe zugrunde, eine Vorrichtung der eingangs genannten Art bereitzustellen, die eine schonende Einbringung des Photosensibilisators in das Augengewebe ermöglicht, insbesondere hinsichtlich der Tiefe. Insbesondere soll auch in einfacher Weise die Quervernetzung im Augengewebe steuerbar sein.The invention has for its object to provide a device of the type mentioned, which allows a gentle introduction of the photosensitizer in the eye tissue, especially in terms of depth. In particular, the cross-linking in ocular tissue should also be controllable in a simple manner.

Hierzu stellt die Erfindung eine Vorrichtung gemäß Anspruch 1 bereit zum Präparieren eines Auges für das Einbringen von Photosensibilisator in Augengewebe.For this purpose, the invention provides a device according to claim 1 for preparing an eye for the introduction of photosensitizer in ocular tissue.

Damit ist es möglich, den Photosensibilisator in einen oder mehrere Kanäle in einfacher Weise einzubringen, ohne dass hierfür erhebliche Teile des Epithels entfernt oder aufgeklappt werden müssen.This makes it possible to introduce the photosensitizer in one or more channels in a simple manner, without the need for this significant parts of the epithelium must be removed or unfolded.

Die für die Erzeugung des Kanals oder der Kanäle eingesetzte Laserstrahlung kann mit als solches bekannten Mitteln erzeugt werden. Bekannt sind die für das Erzeugen der Kanäle erforderlichen Quellen für Laserstrahlung zum Beispiel aus der sogenannten Femto-LASIK. Dort wird Laserstrahlung zum Beispiel eines Femtosekundenlasers als sogenanntes "Laserskalpell" eingesetzt, um Augengewebe durch "Verdampfung" (Kavitationsblasen) mit der Energie des Laserlichts zu schneiden. In der Femto-LASIK wird mit dem Laserskalpell der sogenannte Flapschnitt erzeugt, also ein Deckelchen von der Seite her aus dem Epithelium ausgeschnitten und weggeklappt, um dann mit z. B. einem Excimerlaser im freiliegenden Stroma zur Neuformung der Kornea eine Ablation durchzuführen. Auch gepulste Laser mit Pulslängen im Picosekundenbereich und im Nanosekundenbereich sind zur Erzeugung der Kanäle geeignet.The laser radiation used to create the channel or channels can be generated by means known as such. Are known for generating the channels required sources of laser radiation, for example, from the so-called femto-LASIK. There laser radiation is used, for example, a femtosecond laser as a so-called "laser scalpel" to cut eye tissue by "evaporation" (cavitation bubbles) with the energy of the laser light. In femto-LASIK, the so-called flap cut is produced with the laser scalpel, ie a lid is cut out of the epithelium from the side and folded away. For example, an excimer laser in the exposed stroma to ablate the cornea to perform an ablation. Pulsed lasers with pulse lengths in the picosecond range and in the nanosecond range are also suitable for generating the channels.

Der Begriff "Kanal" im Sinne der vorliegenden Erfindung bedeutet keine Schnittfläche zur Erzeugung eines sogenannten Flaps, wie er bei der Femtosekunden-LASIK bekannt ist.The term "channel" in the sense of the present invention does not mean a cut surface for producing a so-called flap, as it is known in femtosecond LASIK.

Die für die vorliegende Erfindung eingesetzten Mittel zum Führen und Fokussieren der Laserstrahlung in Bezug auf das Augengewebe können dieser Technik entnommen werden. Gemäß der Erfindung wird der die optischen Mittel zum Führen und Fokussieren der Laserstrahlung steuernde Rechner aber erfindungsgemäß derart programmiert, dass die Fokusse der Laserstrahlung nacheinander so entlang einer geraden oder gekrümmten Linie bewegt werden, dass durch sogenannte Kavitationsblasen im Gewebe ein Kanal oder mehrere Kanäle entstehen, die ausgehend von der Oberfläche des Augengewebes, also insbesondere der Hornhaut, in das Innere des Augengewebes reichen, so dass ein Photosensibilisator, der an den Eingang des Kanals gebracht wird, in den Kanal und damit in das Innere des Augengewebes eindringen kann. Dabei werden die Kanäle bevorzugt so erzeugt, dass die einzelnen benachbarten Kavitationsblasen jeweils einen solchen Abstand zueinander haben ("spacing"), dass die Struktur und Stabilität des Gewebes möglichst wenig beeinträchtigt wird. Der Abstand zwischen den Kavitationsblasen, welche den Kanal erzeugen, soll aber auch andererseits so gering sein, dass der in Form einer Lösung in den Kanal eingeführte Photosensibilisator, z. B. Riboflavin, in der gewünschten Weise durch den Kanal, also sozusagen von Kavitationsblase zu Kavitationsblase in das Gewebe eindringt. In den Bereichen zwischen benachbarten Kavitationsblasen erfolgt also das Eindringen der Photosensibilisator-Lösung durch Diffusion. Somit ist im Sinne dieser Erfindung der Begriff "Kanal" nicht notwendig als durchgehender, völlig von Gewebe befreiter Hohlraum zu verstehen, obwohl andererseits auch völlig durchgehende Kanäle im Sinne der Erfindung denkbar sind.The means used for the present invention for guiding and focusing the laser radiation with respect to the eye tissue can be taken from this technique. According to the invention, however, the computer controlling the optical means for guiding and focusing the laser radiation is, according to the invention, programmed in such a way that the foci of the laser radiation successively follow one another Straight or curved line are moved so that so-called cavitation bubbles in the tissue, a channel or multiple channels arise, which extend from the surface of the eye tissue, ie in particular the cornea, in the interior of the eye tissue, so that a photosensitizer, which at the entrance of the Channel is brought into the canal and thus into the interior of the eye tissue can penetrate. In this case, the channels are preferably produced in such a way that the individual adjacent cavitation bubbles each have such a distance from each other ("spacing") that the structure and stability of the tissue is impaired as little as possible. On the other hand, the distance between the cavitation bubbles which produce the channel should also be so small that the photosensitizer introduced into the channel in the form of a solution, e.g. B. riboflavin, penetrates in the desired manner through the channel, so to speak, from Kavitationsblase to Kavitationsblase in the tissue. In the areas between adjacent cavitation bubbles, therefore, the penetration of the photosensitizer solution takes place by diffusion. Thus, for the purposes of this invention, the term "channel" is not necessarily to be understood as a continuous, completely tissue-free cavity, although on the other hand, completely continuous channels within the meaning of the invention are conceivable.

Gemäß einer Variante der Erfindung kann der Kanal auch einer gekrümmten Linie folgen, da durch die Fokussierung der Laserstrahlung im Inneren des Gewebes mit Fokus-Punkten entlang der gekrümmten Linie auch eine von der geraden Linie abweichende Kanalform erzeugbar ist. Bei allen genannten Kanalformen kann durch Aneinanderreihung der Fokusse der Laserstrahlung mit hinreichend dichtem Abstand durch sie sogenannte "Photodisruption" der Kanal mit gewünschtem Durchmesser und mit gewünschtem geometrischen Verlauf erzeugt werden.According to a variant of the invention, the channel can also follow a curved line, since by focusing the laser radiation in the interior of the tissue with focus points along the curved line, a channel shape deviating from the straight line can be generated. In all the mentioned channel shapes can be created by stringing the foci of the laser radiation with a sufficiently dense distance through them so-called "photodisruption" of the channel with the desired diameter and with the desired geometric course.

Die Erfindung ermöglicht es auch, die Dichte der Kanäle im Augengewebe unterschiedlich, abhängig vom Ort im Augengewebe, einzustellen, also an gewünschten Stellen des Augengewebes mehr Kanäle zu setzen als an anderen Stellen, was dann zur Folge hat, dass dort, wo die Kanaldichte größer ist, auch die Dichte des Photosensibilisators im Gewebe höher ist und damit auch die biomechanische und biochemische Wirkung an solchen Stellen anders ist als an jenen Stellen im Augengewebe, an denen die Kanaldichte geringer ist.The invention also makes it possible to adjust the density of the channels in the eye tissue differently, depending on the location in the eye tissue, ie to set more channels at desired sites of the eye tissue than at other locations, which then has the consequence that where the canal density is greater is also the density of the photosensitizer in the tissue is higher and thus the biomechanical and biochemical effect at such sites is different than those in the eye tissue in which the channel density is lower.

Auch kann die Dichte des im Augengewebe letztlich zur Wirkung kommenden Photosensibilisators dadurch gesteuert werden, dass die Tiefe der Kanäle in der Kornea ortsabhängig variiert wird.The density of the photosensitizer ultimately acting in the eye tissue can also be controlled by varying the depth of the channels in the cornea in a location-dependent manner.

Ebenso kann die Dichte des in das Augengewebe einzubringenden Photosensibilisators dadurch gesteuert werden, dass der Querschnitt des einen oder der mehreren Kanäle mehr oder weniger groß gewählt wird.Also, the density of the photosensitizer to be introduced into the eye tissue can be controlled by making the cross section of the one or more channels more or less large.

Die Breite eines Kanals liegt bevorzugt im Bereich von 0,1 mm2 bis 1,2 mm, wobei jedes Subintervall darin ebenfalls hier offenbart ist.The width of a channel is preferably in the range of 0.1 mm 2 to 1.2 mm, with each subinterval therein also disclosed herein.

Wenn hier von "Kanal" die Rede ist, meint dies immer den Singular oder den Plural.When referring to "channel", it always means singular or plural.

Mit der erfindungsgemäßen Vorrichtung kann also ein Kanalsystem in der Hornhaut erzeugt werden, das einen Zugang von außen in das Innere der Hornhaut ermöglicht. Die Photosensibilisator-Lösung kann dann eingespritzt werden, so dass sie sich im Hornhautstroma verteilt. Hierfür kann das Kanalsystem, je nach der ophthalmologischen Indikation, einen oder mehrere Kanäle aufweisen, wobei zum Beispiel bei einer gewünschten homogenen Verteilung des Photosensibilisators die Dichte der Kanäle (also die Anzahl der Kanäle pro Flächeneinheit oder pro Volumeneinheit) im Wesentlichen homogen ist im behandelten Bereich der Kornea. Zum Beispiel können vier Kanäle in die vier Korneasegmente gesetzt werden, entsprechend den vier Segmenten der Projektion der Kornea auf eine Ebene. Das Kanalsystem kann auch stochastisch generiert werden.With the device according to the invention, therefore, a channel system can be created in the cornea, which allows access from the outside to the interior of the cornea. The photosensitizer solution can then be injected so that it spreads in the corneal stroma. For this purpose, the channel system, depending on the ophthalmological indication, have one or more channels, for example, with a desired homogeneous distribution of the photosensitizer, the density of the channels (ie the number of channels per unit area or per unit volume) is substantially homogeneous in the treated area the cornea. For example, four channels may be placed in the four corneal segments, corresponding to the four segments of corneal projection onto a plane. The channel system can also be generated stochastically.

Auch können die Querschnitte der einzelnen Kanäle durch entsprechende Steuerung der Fokusse der Laserstrahlung wahlweise gestaltet werden, zum Beispiel kreisförmig, rechteckförmig, quadratisch, oder auch oval bzw. schlitzförmig.Also, the cross-sections of the individual channels can be designed by appropriate control of the focuses of the laser radiation optionally, for example, circular, rectangular, square, or even oval or slit-shaped.

Bevorzugt erstrecken sich die Kanäle im Wesentlichen quer zur Achse (A) des Auges. Der Begriff "quer" bedeutet hier im Wesentlichen "radial". "Radial" bedeutet eine Richtung ausgehend vom Apex der Kornea nach außen.Preferably, the channels extend substantially transversely to the axis (A) of the eye. The term "transverse" here essentially means "radial". "Radial" means a direction outward from the apex of the cornea.

Eine Ausgestaltung der Erfindung sieht vor, dass der oder die Kanäle im Wesentlichen die gesamte radiale Fläche der Kornea mit im Wesentlichen gleichförmiger Kanaldichte durchziehen. Dies bedeutet, mit anderen Worten, dass mindestens in einer vorgegebenen Fläche in vorgegebener Tiefe der Kornea Photosensibilisator durch Diffusion homogen (gleichförmig mit gleicher Dichte) in das Komeagewebe gebracht wird.An embodiment of the invention provides that the channel (s) traverses substantially the entire radial surface of the cornea with a substantially uniform channel density. This means, in other words, that at least in a given area at a given depth the cornea photosensitizer is brought into the comatom by diffusion homogeneously (uniformly with the same density).

Es ist vorgesehen, dass der eine oder die mehreren Kanäle mit mehr als einer Öffnung verbunden sind, wobei die genannteIt is contemplated that the one or more channels are connected to more than one opening, said one

Öffnung in die Oberfläche des Augengewebes reicht, so dass Photosensibilisator ohne Hindernis in den oder die Kanäle einbringbar ist, z. B. mit einer feinen Spritze oder dergleichen.Opening in the surface of the eye tissue is sufficient so that photosensitizer without obstruction in the one or more channels can be introduced, for. B. with a fine syringe or the like.

Die genannten Öffnungen, durch welche die Kanäle von außen zugänglich sind, werden bevorzugt an oder nahe dem Rand der Kornea, also an oder nahe dem Limbus, angeordnet.The said openings, through which the channels are accessible from the outside, are preferably arranged at or near the edge of the cornea, ie at or near the limbus.

Die Erzeugung von Kanälen oder Hohlräumen im Sinne der vorliegenden Erfindung ist also verschieden von der Erzeugung eines sogenannten Flaps für die LASIK, d. h. die erfindungsgemäßen Kanäle bzw. Hohlräume bewirken nicht die Erzeugung eines Flaps ("Deckelchens"), welches zur Seite geklappt werden kann.The generation of channels or cavities in the sense of the present invention is thus different from the generation of a so-called flap for the LASIK, d. H. the channels or cavities according to the invention do not cause the generation of a flap ("Deckelchens"), which can be folded to the side.

Eine andere bevorzugte Ausgestaltung der Erfindung sieht vor, dass zumindest ein Teil der Kanäle spiralförmig verläuft.Another preferred embodiment of the invention provides that at least a part of the channels runs in a spiral shape.

Bei allen beschriebenen Ausgestaltungen und Ausführungsbeispielen der Erfindung kann auch ein Gas, insbesondere Luft, in einen oder mehrere Kanäle bzw. Hohlräume injiziert werden.In all described embodiments and embodiments of the invention, a gas, in particular air, can be injected into one or more channels or cavities.

Weitere bevorzugte Ausgestaltungen der Erfindung sind in den weiteren abhängigen Ansprüchen beschrieben.Further preferred embodiments of the invention are described in the further dependent claims.

Nachfolgend wird die Erfindung mit weiteren Einzelheiten anhand der Zeichnung näher erläutert.The invention will be explained in more detail with reference to the drawings.

Es zeigt:

  • Fig. 1 schematisch eine Vorrichtung zum Präparieren eines Auges für das Einbringen eines Photosensibilisators in Augengewebe;
  • Fig. 2 eine Hornhaut in Draufsicht mit einer schematischen Erläuterung der Erzeugung von Kanälen darin;
  • Fig. 3 ein anderes Ausführungsbeispiel der Erfindung, bei der der Rechner so programmiert ist, dass er etwa kreissektorförmige Kanalgebilde im Augengewebe erzeugt zur Behandlung von insbesondere Astigmatismus;
  • Fig. 4 einen axialen Schnitt durch eine Kornea mit Kanälen, die in unterschiedlichen Tiefen, bezogen auf die Oberfläche der Kornea, verlaufen; und
  • Fig. 5 eine axiale Draufsicht auf eine Kornea, bei der zumindest ein Ring als Kanal geformt ist zur Behandlung von Hyperopie.
It shows:
  • Fig. 1 schematically a device for preparing an eye for the introduction of a photosensitizer in ocular tissue;
  • Fig. 2 a cornea in plan view with a schematic explanation of the generation of channels therein;
  • Fig. 3 another embodiment of the invention, wherein the computer is programmed so that it generates approximately circular sector-shaped channel structures in the eye tissue for the treatment of particular astigmatism;
  • Fig. 4 an axial section through a cornea with channels that extend at different depths with respect to the surface of the cornea; and
  • Fig. 5 an axial plan view of a cornea, wherein at least one ring is formed as a channel for the treatment of hyperopia.

Fig. 1 zeigt schematisch ein Auge 10, das durch Einbringen von Photosensibilisator hinsichtlich seiner biomechanischen und/oder biochemischen Eigenschaften verändert werden soll. Als solches ist dieser Vorgang als "korneales Crosslinking" bekannt. Zum Beispiel kann durch das "Crosslinking", also die sogenannte Quervernetzung, die mechanische Stabilität der Hornhaut verstärkt werden. Durch Einsatz von Formkörpern kann auch die Form der Hornhaut während der Kanalentstehung oder der Quervernetzung verändert werden. Darüber hinaus ist der Einsatz von Photosensibilisatoren auch geeignet, infektiöse Entzündungen der Hornhaut zu behandeln, wobei die entstehenden Radikale eingedrungene Keime töten. Fig. 1 schematically shows an eye 10 to be changed by introducing photosensitizer with regard to its biomechanical and / or biochemical properties. As such, this process is known as "corneal crosslinking." For example, the cross-linking, so-called cross-linking, enhances the mechanical stability of the cornea. The use of moldings can also change the shape of the cornea during channeling or cross-linking. In addition, the use of photosensitizers is also suitable for treating infectious inflammations of the cornea, with the resulting radicals killing invading germs.

Eine Augenachse ist mit "A" bezeichnet, wobei diese Augenachse im wesentlichen auch zusammenfällt mit der optischen Achse der weiter unten näher beschriebenen Mittel zum Führen und Fokussieren von Laserstrahlung.An eye axis is designated by "A", this eye axis substantially coinciding with the optical axis of the means described below in more detail for guiding and focusing laser radiation.

Das Zentrum (Mittelpunkt) der Hornhautoberfläche (14a) ist mit "M" bezeichnet, so dass hiervon ausgehend eine radiale Richtung R definiert werden kann.The center (center) of the corneal surface (14a) is denoted by "M", so that a radial direction R can be defined therefrom.

Das durch Quervernetzung zu behandelnde Augengewebe 12 ist hier im wesentlichen die Hornhaut (Kornea) 16, die nach außen durch das Epithel 14 abgedeckt ist.Here, the eye tissue 12 to be cross-linked is substantially the cornea (cornea) 16 which is covered outwardly by the epithelium 14.

Mit der noch näher zu beschreibenden Vorrichtung werden Kanäle 18 in das Stroma der Hornhaut 16 eingebracht, wobei die Kanäle 18 mit Öffnungen 0 (Ports) flüssigkeitsleitend verbunden sind und die Öffnungen O einen Zugang von außen in die Kanäle für das Eingeben von Photosensibilisator-Lösung ermöglichen. Die Kanäle 18 reichen in das Innere der Hornhaut 16 und enden vor deren innerer Oberfläche 16a.With the device to be described later, channels 18 are inserted into the cornea 16, the channels 18 being fluidly connected to ports 0 (ports), and the ports O allowing external access to the channels for entering photosensitizer solution , The channels 18 extend into the interior of the cornea 16 and terminate before the inner surface 16 a.

In die Kanäle 18 wird ein Photosensibilisator, z.B.Riboflavin, eingebracht, welches in die Kanäle eindringt und sich von dort ausgehend durch Diffusion im Hornhautgewebe verteilt.In the channels 18, a photosensitizer, for example riboflavin, is introduced, which penetrates into the channels and spreads therefrom by diffusion in the corneal tissue.

Die Vorrichtung weist eine Quelle 20 für Laserstrahlung auf, z.B. einen oben erläuterten Femtosekundenlaser, wie er z.B. zum Schneiden eines Flap in der Femto-LASIK eingesetzt wird. Auch hinsichtlich der Mittel 24 zum Führen und Fokussieren der Laserstrahlung 26 im Inneren der Hornhaut 16 kann auf entsprechende Mittel, wie sie aus der Femto-LASIK als solches bekannt sind, zurückgegriffen werden.The device has a source 20 for laser radiation, for example a femtosecond laser as explained above, as for example for cutting a flap in the femto-LASIK is used. With regard to the means 24 for guiding and focusing the laser radiation 26 in the interior of the cornea 16, appropriate means known per se from femto-LASIK can also be used.

Im Unterschied zur LASIK ist ein Rechner 22, der die Laserstrahlquelle 20 und die optischen Mittel 24 zum Führen und Fokussieren der Laserstrahlung 26 steuert, mit einem Programm P programmiert, das die Laserstrahlung 26 in besonderer Weise zur Erzeugung der Kanäle 18 steuert. Hierzu wird bei Erzeugung der genannten Kanäle 18 gemäß Fig. 1 die Laserstrahlung 26 in Richtung der Pfeile 28 parallel verschoben. Die Darstellung gemäß Fig. 1 zeigt einen die Achse A enthaltenden Schnitt durch das Auge. In Fig. 1 ist ein Kanal 18 gezeigt, der im Wesentlichen parallel zur Oberfläche 14a der Kornea verläuft. Der Kanal ist über eine Öffnung O, die nahe dem Limbus 30 liegt, von außen zugänglich. Zum Beispiel kann eine feine Spritze in die Öffnung O eingeführt werden, um eine Photosensibilisator-Lösung oder ein Gas, wie Luft, in den Kanal 18 einzuspritzen.In contrast to LASIK, a computer 22, which controls the laser beam source 20 and the optical means 24 for guiding and focusing the laser radiation 26, is programmed with a program P which controls the laser radiation 26 in a special way for generating the channels 18. For this purpose, when generating said channels 18 according to Fig. 1 the laser radiation 26 is displaced parallel in the direction of the arrows 28. The representation according to Fig. 1 shows a section A containing the axis A through the eye. In Fig. 1 a channel 18 is shown which is substantially parallel to the surface 14a of the cornea. The channel is accessible via an opening O, which is located near the limbus 30, from the outside. For example, a fine syringe may be introduced into the opening O to inject a photosensitizer solution or a gas, such as air, into the channel 18.

Fig. 2 zeigt eine Draufsicht auf eine Kornea 16 und einen im Inneren der Kornea 16 verlaufenden Kanal 18, der beim dargestellten Ausführungsbeispiel spiralförmig ist mit zusätzlichen Öffnungen O, die in Umfangsrichtung C unter Abständen verteilt sind. Die etwa spiralförmig verlaufenden Kanäle 18 sind beim dargestellten Ausführungsbeispiel in einer Fläche angeordnet, die sich im Wesentlichen parallel zur Oberfläche 14a des Auges erstreckt. In Abwandlung dieses Ausführungsbeispieles können die Kanäle 18 auch in einer Ebene angeordnet sein, die senkrecht zur Achse A steht. Wiederum eine Abwandlung sieht vor, dass die Kanäle in einer Fläche verlaufen, die sich parallel zur Rückfläche 16a der Kornea 16 erstreckt. Die Wahl des Ortes und des Verlaufs der Kanäle 18 kann von der gegebenen medizinischen Indikation abhängen und entsprechend gewählt werden. Fig. 2 shows a plan view of a cornea 16 and a running inside the cornea 16 channel 18 which is in the illustrated embodiment is spiral with additional openings O, which are distributed in the circumferential direction C at intervals. The approximately spirally extending channels 18 are arranged in the illustrated embodiment in a surface which extends substantially parallel to the surface 14a of the eye. In a modification of this embodiment, the channels 18 may also be arranged in a plane which is perpendicular to the axis A. Again, a variation provides that the channels extend in a plane that extends parallel to the back surface 16a of the cornea 16. *** " The choice of location and course of the channels 18 may depend on the given medical indication and be chosen accordingly.

Beim dargestellten Ausführungsbeispiel gemäß Fig. 2 sind die Kanäle so positioniert, dass sie zumindest in der von ihnen aufgespannten Fläche bewirken, dass sich der Photosensibilisator dort durch Diffusion im Wesentlichen homogen im Korneagewebe verteilt.In the illustrated embodiment according to Fig. 2 For example, the channels are positioned such that, at least in the area they define, the photosensitizer diffuses there substantially homogeneously in the corneal tissue.

In Abwandlung der in den Figuren dargestellten Ausführungsbeispiele können Kanäle auch axial, d.h. parallel zur Achse A verlaufen, zumindest teilweise.In a modification of the embodiments shown in the figures, channels may also be axial, i. parallel to the axis A, at least partially.

Kanäle können sich auch radial erstrecken.Channels may also extend radially.

Auch sind alle vorstehend genannten Verläufe und Anordnungen der Kanäle wahlweise miteinander kombinierbar.Also, all the above courses and arrangements of the channels are optionally combinable.

Durch die Wahl der Durchmesser und geometrischen Anordnung der Kanäle kann auch die Verteilung von Photosensibilisator in der Kornea wahlweise, je nach medizinischer Indikation, gesteuert werden.By choosing the diameter and geometric arrangement of the channels, the distribution of photosensitizer in the cornea can be optionally controlled, depending on the medical indication.

Die Kanäle werden durch fokussierte Laserstrahlung, insbesondere mittels eines Femtosekundenlasers, durch Kavitationsblasen, die von den Laserfokussen erzeugt werden, gebildet. Dabei ist bevorzugt vorgesehen, dass benachbarte Kavitationsblasen sich nicht vollständig überlagern, so dass zwischen einzelnen Kavitationsblasen Gewebereste verbleiben, die einerseits das Gesamtgewebe in der Struktur stabilisieren und andererseits hinreichend durchlässig sind für die Diffusion von Photosensibilisator in den Kanälen.The channels are formed by focused laser radiation, in particular by means of a femtosecond laser, by cavitation bubbles generated by the laser focusses. In this case, it is preferably provided that adjacent cavitation bubbles do not completely overlap so that tissue residues remain between individual cavitation bubbles, which on the one hand stabilize the overall tissue in the structure and on the other hand are sufficiently permeable to the diffusion of photosensitizer in the channels.

Es ist auch möglich, statt langgestreckter Kanäle anders geformte Hohlräume durch die genannten Kavitationsblasen zu erzeugen, insbesondere flächige Hohlräume, in denen z. B. unter regelmäßigen kürzeren Abständen Gewebebereiche als "Pfosten" zwischen den Ober- und Unterflächen des Hohlraumes oder der Hohlräume verbleiben.It is also possible, instead of elongated channels to produce differently shaped cavities through said cavitation bubbles, in particular flat cavities in which z. B. at regular shorter intervals tissue areas as "posts" remain between the top and bottom surfaces of the cavity or cavities.

Fig. 3 zeigt in axialer Draufsicht eine Kornea mit einem Kanalsystem 18', 18", das zur Behandlung von Astigmatismus in der Kontur etwa kreissektorförmig (wie dargestellt) geformt ist. Dabei können z. B. gemäß Fig. 3 zwei kreissektorförmige Kanalsysteme 18' bzw. 18" ausgeformt sein, mit jeweils einem unterschiedlichen Sektorwinkel α1 bzw. α2. Fig. 3 shows in axial plan view a cornea with a channel system 18 ', 18 ", which is shaped in the shape of a sector of a circle (as shown) for the treatment of astigmatism in the contour Fig. 3 be formed two circular sector-shaped channel systems 18 'and 18 ", each with a different sector angle α 1 and α 2 .

Fig. 4 zeigt Kanäle 18a, 18b, 18c, die in unterschiedlichen Tiefen, bezogen auf die Oberfläche 14a der Kornea, verlaufen. Die in Fig. 4 schematisch gezeigten unterschiedlichen drei Tiefen für die Kanäle können für sämtliche hier im Einzelnen mitgeteilten Strukturen und Anordnungen von Kanälen gemäß den Figuren 1, 2, 3 und 5 sowie anderen Ausführungsbeispielen verwirklicht werden. Fig. 4 shows channels 18a, 18b, 18c which extend at different depths relative to the surface 14a of the cornea. In the Fig. 4 The various three depths for the channels shown schematically may be used for all of the structures and arrangements of channels detailed herein FIGS. 1, 2 . 3 and 5 as well as other embodiments.

Fig. 5 zeigt einen ringförmigen Kanal 18"' in schematischer Draufsicht mit zwei Öffnungen O, die den Kanal 18"' mit der Oberfläche der Kornea verbinden. In Abwandlung des Ausführungsbeispiels gemäß Fig. 5 können auch mehrere ringförmige Kanäle vorgesehen sein, die entweder untereinander und/oder jeweils einzeln mit der Oberfläche der Kornea flüssigkeitsleitend verbunden sind. Fig. 5 shows an annular channel 18 "'in a schematic plan view with two openings O, which connect the channel 18"' with the surface of the cornea. In a modification of the embodiment according to Fig. 5 can also be provided a plurality of annular channels, which are connected fluid-conducting either with each other and / or each individually with the surface of the cornea.

Die Erfindung beinhaltet auch ein Verfahren zum Präparieren eines Auges für das Einbringen von Photosensibilisator, wobei mittels Laserstrahlung 26, die auf und in die Hornhaut fokussiert wird, Kanäle 18 in der Hornhaut erzeugt werden, die sich von der Oberfläche 14a der Kornea ausgehend in das Innere der Kornea erstrecken. Bei diesem Verfahren können alle oben beschriebenen Merkmale und Eigenschaften der Kanäle 18 eingesetzt werden.

10
Auge
M
Mittelpunkt (von 10)
A
Augenachse
P
Programm
C
Umfangsrichtung
O
Öffnung
12
Augengewebe
14
Epithel, 14a Oberfläche (von 14)
16
Kornea, 16a Rückfläche (von 16)
18
Kanal
20
Quelle für Laserstrahlung
22
Rechner
24
Mittel
26
Laserstrahlung
28
Pfeile
30
Limbus
The invention also includes a method for preparing an eye for introducing photosensitizer, wherein channels 18 are created in the cornea by laser radiation 26 focused on and in the cornea, which extend from the surface 14a of the cornea into the interior the cornea extend. In this method, all the features and properties of the channels 18 described above can be used.
10
eye
M
Midpoint (out of 10)
A
eye axis
P
program
C
circumferentially
O
opening
12
eye tissue
14
Epithelium, 14a surface (from 14)
16
Cornea, 16a posterior surface (from 16)
18
channel
20
Source for laser radiation
22
computer
24
medium
26
laser radiation
28
arrows
30
limbo

Claims (14)

  1. An apparatus for preparing an eye (10) for applying a photosensibilisator into the eye's tissue (12), comprising:
    - a source (20) for laser radiation,
    - means (24) for guiding and focusing the laser radiation (26) in relation to the eye's tissue (12), further comprising
    - a computer (22) for controlling said means (24), wherein the computer (22) is programmed to control the laser ration (26) such that the laser radiation generates in the eye's tissue (12) at least one channel (18) extending to the inner of the eye's tissue and generates one or more orifices (O) in the surface (14a) of the eye's tissue,
    characterized in that the computer is programmed to control said means (24) such that the one or more channels (18) are communicating with one or more orifices (O) in the surface (14a) of the eye's tissue.
  2. The apparatus according to claim 1, characterized in that the one or more channels (18) extend a substantially transverse to the axis (A) of the eye.
  3. The apparatus according to claim 1 or 2, characterized in that the computer (22) is programmed to control said means (24) such that the one or more channels (18) are applied into the eye's tissue (12) along lines extending substantially radially (R).
  4. The apparatus according to any one of claims 1, 2 or 3, characterized in that the one or more channels (18) penetrate substantially the entire radial surface of the cornea (16) while having a substantially uniform channel density.
  5. The apparatus according to any one of the preceding claims, characterized in that at least a part of the channels extends spirally.
  6. The apparatus according to any one of the preceding claims, characterized in that the one or more channels (18) are generated at least partially by cavitation bubbles generated by the laser radiation, wherein the cavitation bubbles partially do not transit continually into one another, wherein the distance between neighboring cavitation bubbles is in the range from 1 to 50 µm, preferably in the range from 5 to 30 µm and particularly preferable in the range of 10 to 20 µm.
  7. The apparatus according to any one of the preceding claims, characterized in that at least a part of the channels extends at least partially axially and/or at least partially curved.
  8. The apparatus according to claim 1, characterized in that the computer (22) is programmed so as to control said means (24) such that channels (18) are applied into the eye's tissue (12), the density of which varies depending on the site in the eye's tissue.
  9. The apparatus according to any one of the preceding claims, characterized in that the computer (22) is programmed to control said means (24) such that channels (18) are applied into eye's tissue (12), the depth and/or the section of which varies depending on the site in the eye's tissue.
  10. The apparatus according to any one of the preceding claims, characterized in that the computer (22) is programmed to control said means (24) such that channels (18) are applied into the eye's tissue (12), wherein different channels have different sections.
  11. The apparatus according to any one of the preceding claims, characterized in that the source (20) for laser radiation is one of a femtosecond laser, a nanosecond laser or a picosecond laser.
  12. The apparatus according to any one of the preceding claims, characterized in that the computer is programmed to control said means (24) such that channels (18', 18") are generated into the eye's tissue for therapy of astigmatism, which channels approximately take the form of sectors.
  13. The apparatus according to any one of the preceding claims, characterized in that the computer (22) is programmed to control said means (24) so as to generate one or more channels (18'") extending at least approximately annularly.
  14. The apparatus according to any one of the preceding claims, characterized in that the computer (22) is programmed to control said means (24) such that channels (18a, 18b, 18c) are generated into the eye's tissue (12), which channels extend in different depths in the eye's tissue.
EP10006607.5A 2010-06-24 2010-06-24 Device for preparing an eye for introducing a photostabilizer Active EP2407132B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES10006607.5T ES2469868T3 (en) 2010-06-24 2010-06-24 Device for preparing an eye to apply a photosensitizer
EP10006607.5A EP2407132B1 (en) 2010-06-24 2010-06-24 Device for preparing an eye for introducing a photostabilizer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10006607.5A EP2407132B1 (en) 2010-06-24 2010-06-24 Device for preparing an eye for introducing a photostabilizer

Publications (2)

Publication Number Publication Date
EP2407132A1 EP2407132A1 (en) 2012-01-18
EP2407132B1 true EP2407132B1 (en) 2014-04-30

Family

ID=42727660

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10006607.5A Active EP2407132B1 (en) 2010-06-24 2010-06-24 Device for preparing an eye for introducing a photostabilizer

Country Status (2)

Country Link
EP (1) EP2407132B1 (en)
ES (1) ES2469868T3 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729716B2 (en) 2012-03-29 2020-08-04 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
US11033429B2 (en) 2010-09-30 2021-06-15 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2830627B1 (en) 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
US20130310728A1 (en) * 2012-05-16 2013-11-21 Theo Seiler Device for dissecting an eye for the introduction of photosensitizer and method of refractive surgery
US20150057644A1 (en) * 2012-10-30 2015-02-26 Wavelight Gmbh Stabilizing lenticules used for refractive correction
PL2948113T3 (en) * 2013-01-28 2018-08-31 Novartis Ag Apparatus for corneal crosslinking
US9907698B2 (en) 2013-06-25 2018-03-06 TECLens, LLC Apparatus for phototherapy of the eye
CN105555237B (en) * 2013-10-09 2018-01-12 视乐有限公司 For splitting eyes to introduce the equipment of sensitising agent
DE102014012675A1 (en) * 2014-08-26 2016-03-03 Wavelight Gmbh Crosslinking of eye tissue
DE102014016990B3 (en) 2014-11-18 2016-02-11 Wavelight Gmbh Nozzle unit for cross-linking of eye tissue

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1854438A1 (en) * 2006-05-09 2007-11-14 Iroc AG Ophthalmologic device for preventing myopia
EP1561440B1 (en) * 2004-02-03 2009-04-08 Iroc AG Ophtalmological device

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006030219A1 (en) 2006-06-30 2008-01-03 Iroc Ag Irradiation system for medical applications
US8740888B2 (en) * 2008-01-18 2014-06-03 Technolas Perfect Vision Gmbh Computer control for bio-mechanical alteration of the cornea

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1561440B1 (en) * 2004-02-03 2009-04-08 Iroc AG Ophtalmological device
EP1854438A1 (en) * 2006-05-09 2007-11-14 Iroc AG Ophthalmologic device for preventing myopia

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033429B2 (en) 2010-09-30 2021-06-15 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
US11135090B2 (en) 2010-09-30 2021-10-05 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
US12156834B2 (en) 2010-09-30 2024-12-03 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
US10729716B2 (en) 2012-03-29 2020-08-04 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
US11497766B2 (en) 2012-03-29 2022-11-15 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress

Also Published As

Publication number Publication date
EP2407132A1 (en) 2012-01-18
ES2469868T3 (en) 2014-06-20

Similar Documents

Publication Publication Date Title
EP2407132B1 (en) Device for preparing an eye for introducing a photostabilizer
EP1834615B1 (en) Control program for ophthalmologic surgery
WO2005070358A1 (en) Control device for a surgical laser
EP2907489A1 (en) Device for integrating ocular tissue with electromagnetic radiation
DE69024558T2 (en) Laser melting of surfaces
WO2016135111A1 (en) Ophthalmological laser therapy device for producing corneal access incisions
WO2017194567A1 (en) Method for eye surgery
EP3200737B1 (en) Planning device and method for generating control data for an eye surgical treatment device
EP3695817B1 (en) Treatment device for controlling an ophthalmic surgical laser
DE102017209574A1 (en) Devices and methods for preparing and performing corneal tattoos
EP3695818B1 (en) Computerprogram for controlling an ophthalmic surgical laser and treatment device
DE102009009382A1 (en) Control data producing device for controlling treatment device for corrective surgery of defective vision of eye of patient, determines control data such that volumes lying at edge of lamella are ablated or removed according to control data
DE102020112277A1 (en) Method for providing control data for an ophthalmic surgical laser and method for controlling a treatment device
WO2016050779A1 (en) Creating cuts in a transparent material using optical radiation
WO2023057443A1 (en) Planning device for generating control data for a laser device of a treatment apparatus for refractive correction of an eye, treatment apparatus, method for generating control data and method for refractive correction
EP2410960A1 (en) Device for lasik
DE102021116497A1 (en) Method for controlling an ophthalmic surgical laser, treatment device, computer program and computer-readable medium
DE102021101119A1 (en) Method for controlling an ophthalmic surgical laser and treatment device
DE102021132290B4 (en) Method for controlling a laser of a laser device, laser device, computer program and computer-readable medium
DE102020104687A1 (en) Method for controlling an ophthalmic laser and treatment device
DE102020123611B4 (en) System for controlling an eye surgical laser and method for determining control data for controlling an eye surgical laser
DE102020133189B4 (en) Method for controlling an ophthalmic surgical laser and treatment device
DE102019134146B4 (en) Method for controlling an ophthalmic laser and treatment device
DE102022116734B4 (en) Devices and methods for providing a volume body of a cornea for implantation of the volume body into an eye of a patient
DE102019135607B4 (en) Method for controlling an ophthalmic surgical laser and treatment device

Legal Events

Date Code Title Description
17P Request for examination filed

Effective date: 20110307

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FALCON TRADING AG

17Q First examination report despatched

Effective date: 20120208

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IROC INNOCROSS AG

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SEILER, THEO, JUN.

Inventor name: KRAUSE, JOHANNES

Inventor name: SEILER, THEO, PROF.DR.

RTI1 Title (correction)

Free format text: DEVICE FOR PREPARING AN EYE FOR INTRODUCING A PHOTOSTABILIZER

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WAVELIGHT GMBH

Owner name: IROC INNOCROSS AG

RIC1 Information provided on ipc code assigned before grant

Ipc: A61F 9/01 20060101AFI20121031BHEP

Ipc: A61F 9/008 20060101ALI20121031BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20130917

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WAVELIGHT GMBH

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140128

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SEILER, THEO G., JUN.

Inventor name: KRAUSE, JOHANNES

Inventor name: SEILER, THEO, PROF.DR. DR.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 664597

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502010006772

Country of ref document: DE

Effective date: 20140612

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2469868

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140620

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20140430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140731

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140830

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140730

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140730

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140624

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502010006772

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

26N No opposition filed

Effective date: 20150202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140624

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502010006772

Country of ref document: DE

Effective date: 20150202

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100624

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140630

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 664597

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150624

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140430

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: ALCON INC., CH

Free format text: FORMER OWNER: WAVELIGHT GMBH, DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20200116 AND 20200122

Ref country code: DE

Ref legal event code: R082

Ref document number: 502010006772

Country of ref document: DE

Representative=s name: WUESTHOFF & WUESTHOFF, PATENTANWAELTE PARTG MB, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 502010006772

Country of ref document: DE

Owner name: ALCON INC., CH

Free format text: FORMER OWNER: WAVELIGHT GMBH, 91058 ERLANGEN, DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: ALCON INC.

Effective date: 20200423

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230504

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230707

Year of fee payment: 14

Ref country code: CH

Payment date: 20230702

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240516

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240522

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240524

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240530

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240701

Year of fee payment: 15

Ref country code: ES

Payment date: 20240703

Year of fee payment: 15